DE60304059D1 - 3-(2-hydroxy-phenyl)-1h-pyrazol-4-carbonsäureamid derivate als hsp90 inhibitoren zur behandlung von krebs - Google Patents

3-(2-hydroxy-phenyl)-1h-pyrazol-4-carbonsäureamid derivate als hsp90 inhibitoren zur behandlung von krebs

Info

Publication number
DE60304059D1
DE60304059D1 DE60304059T DE60304059T DE60304059D1 DE 60304059 D1 DE60304059 D1 DE 60304059D1 DE 60304059 T DE60304059 T DE 60304059T DE 60304059 T DE60304059 T DE 60304059T DE 60304059 D1 DE60304059 D1 DE 60304059D1
Authority
DE
Germany
Prior art keywords
cancer
treatment
hydroxy
pyrazole
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60304059T
Other languages
English (en)
Other versions
DE60304059T2 (de
Inventor
Mandy Christine Beswick
Paul Andrew Brough
Martin James Drysdale
Brian William Dymock
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute of Cancer Research
Vernalis Cambridge Ltd
Cancer Research Technology Ltd
Original Assignee
Institute of Cancer Research
Vernalis Cambridge Ltd
Cancer Research Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute of Cancer Research, Vernalis Cambridge Ltd, Cancer Research Technology Ltd filed Critical Institute of Cancer Research
Publication of DE60304059D1 publication Critical patent/DE60304059D1/de
Application granted granted Critical
Publication of DE60304059T2 publication Critical patent/DE60304059T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Transplantation (AREA)
  • Gynecology & Obstetrics (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE60304059T 2002-12-05 2003-12-04 3-(2-hydroxy-phenyl)-1h-pyrazol-4-carbonsäureamid derivate als hsp90 inhibitoren zur behandlung von krebs Expired - Lifetime DE60304059T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0228417 2002-12-05
GBGB0228417.2A GB0228417D0 (en) 2002-12-05 2002-12-05 Pyrazole compounds
PCT/GB2003/005275 WO2004050087A1 (en) 2002-12-05 2003-12-04 3-(2-hydroxy-phenyl)-1h-pyrazole-4-carboxylic acid amide derivatives as hsp90 inhibitors for the treatment of cancer

Publications (2)

Publication Number Publication Date
DE60304059D1 true DE60304059D1 (de) 2006-05-11
DE60304059T2 DE60304059T2 (de) 2006-11-16

Family

ID=9949145

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60304059T Expired - Lifetime DE60304059T2 (de) 2002-12-05 2003-12-04 3-(2-hydroxy-phenyl)-1h-pyrazol-4-carbonsäureamid derivate als hsp90 inhibitoren zur behandlung von krebs

Country Status (11)

Country Link
US (1) US7803831B2 (de)
EP (1) EP1567151B1 (de)
JP (1) JP4575779B2 (de)
CN (1) CN1744894A (de)
AT (1) ATE320252T1 (de)
AU (1) AU2003285584A1 (de)
BR (1) BR0316146A (de)
CA (1) CA2508574A1 (de)
DE (1) DE60304059T2 (de)
GB (1) GB0228417D0 (de)
WO (1) WO2004050087A1 (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR044586A1 (es) * 2003-06-04 2005-09-21 Aventis Pharma Sa Productos aril - heteroaromaticos, composiciones que los contienen y su utilizacion
WO2005063222A1 (ja) * 2003-12-26 2005-07-14 Kyowa Hakko Kogyo Co., Ltd. Hsp90ファミリー蛋白質阻害剤
DE102004039280A1 (de) 2004-08-13 2006-02-23 Merck Patent Gmbh 1,5-Diphenyl-pyrazole
AU2005285953B2 (en) 2004-09-22 2011-01-20 Nippon Kayaku Kabushiki Kaisha Novel block copolymer, micelle preparation, and anticancer agent containing the same as active ingredient
FR2876079A1 (fr) 2004-10-06 2006-04-07 Michel Gautier Dispositif de largage d'un moyen de secours multi-actions, notamment un radeau de sauvetage
DE102004049078A1 (de) 2004-10-08 2006-04-13 Merck Patent Gmbh Phenylpyrazole
ES2594874T3 (es) 2004-11-18 2016-12-23 Synta Pharmaceuticals Corp. Compuestos de triazol que modulan la actividad de HSP90
DE102005009440A1 (de) 2005-03-02 2006-09-07 Merck Patent Gmbh Thienopyridinderivate
EP1857446B1 (de) * 2005-03-09 2013-05-01 Nippon Kayaku Kabushiki Kaisha Zur Krebsbehandlung geeignete Derivate von 3-(2,4-Dihydroxyphenyl)-1,2,4-triazol
US8399464B2 (en) 2005-03-09 2013-03-19 Nippon Kayaku Kabushiki Kaisha HSP90 inhibitor
FR2884252B1 (fr) 2005-04-08 2007-05-18 Aventis Pharma Sa Nouveaux derives d'isoindoles, compositions les contenant, leur preparation et leurs utilisations pharmaceutiques notamment en tant qu'inhibiteurs d'activites de la proteine chaperone hsp90
ME01541B (me) * 2005-04-13 2014-04-20 Astex Therapeutics Ltd DERIVATI HIDROKSIBENZAMIDA l NJIHOVA PRIMJENA KAO INHIBITORA HSP90
FR2885904B1 (fr) 2005-05-19 2007-07-06 Aventis Pharma Sa Nouveaux derives du fluorene, compositions les contenant et utilisation
WO2007021966A1 (en) 2005-08-12 2007-02-22 Synta Pharmaceuticals Corp. Pyrazole compounds that modulate hsp90 activity
JP5118039B2 (ja) 2005-08-18 2013-01-16 シンタ ファーマシューティカルズ コーポレーション Hsp90活性を調節するトリアゾール化合物
CA2618724A1 (en) 2005-08-18 2007-02-22 Synta Pharmaceuticals Corp. Imidazole compounds that modulate hsp90 activity
KR20080106254A (ko) 2006-03-28 2008-12-04 니폰 가야꾸 가부시끼가이샤 탁산류의 고분자 결합체
DE102006023336A1 (de) * 2006-05-18 2007-11-22 Merck Patent Gmbh 1,5-Diphenyl-pyrazole II
WO2007135910A1 (ja) 2006-05-18 2007-11-29 Nippon Kayaku Kabushiki Kaisha ポドフィロトキシン類の高分子結合体
AR061185A1 (es) 2006-05-26 2008-08-13 Chugai Pharmaceutical Co Ltd Compuestos heterociclicos como inhibidores de hsp90. composiciones farmaceuticas.
US7666888B2 (en) 2006-07-20 2010-02-23 Amgen Inc. Substituted azole aromatic heterocycles as inhibitors of 11β-HSD-1
CL2007002123A1 (es) * 2006-07-21 2008-06-13 Irm Llc Compuestos derivados de heteroaril-1h-pirazol, utiles como moduladores del desarrollo y funcion de los linfocitos b.
CA2664852A1 (en) 2006-10-03 2008-04-10 Nippon Kayaku Kabushiki Kaisha High-molecular weight conjugate of resorcinol derivatives
FR2907453B1 (fr) 2006-10-24 2008-12-26 Sanofi Aventis Sa Nouveaux derives du fluorene,compositions les contenant et utilisation
US8334364B2 (en) 2006-11-06 2012-12-18 Nipon Kayaku Kabushiki Kaisha High-molecular weight derivative of nucleic acid antimetabolite
EP2090607B1 (de) 2006-11-08 2015-05-20 Nippon Kayaku Kabushiki Kaisha Polymerderivat eines nukleinsäuremetabolismus-antagonisten
DE102007002715A1 (de) 2007-01-18 2008-07-24 Merck Patent Gmbh Triazolderivat
BRPI0808524A2 (pt) 2007-03-01 2014-11-11 Chugai Pharmaceutical Co Ltd Composto macrocíclico
DE602008002600D1 (de) * 2007-06-15 2010-10-28 Irm Llc Verbindungen und zusammensetzungen als itpkb-inhibitoren
US20100240656A1 (en) * 2007-07-12 2010-09-23 Oryzon Genomics, S.A. Compounds as hsp90 inhibitors
WO2009041570A1 (ja) 2007-09-28 2009-04-02 Nippon Kayaku Kabushiki Kaisha ステロイド類の高分子結合体
JP4792128B2 (ja) 2007-10-12 2011-10-12 アークル インコーポレイテッド 癌に対するhsp90阻害剤としての5−(2−ヒドロキシフェニル)テトラゾール
US8920788B2 (en) 2008-03-18 2014-12-30 Nippon Kayaku Kabushiki Kaisha High-molecular weight conjugate of physiologically active substances
LT5623B (lt) 2008-04-30 2010-01-25 Biotechnologijos Institutas, , 5-aril-4-(5-pakeistieji 2,4-dihidroksifenil)-1,2,3-tiadiazolai kaip hsp90 šaperono slopikliai ir tarpiniai junginiai jiems gauti
EP2284209B1 (de) 2008-05-08 2016-08-31 Nippon Kayaku Kabushiki Kaisha Polymerkonjugat aus folsäure oder einem folsäurederivat
CA2740366A1 (en) * 2008-10-21 2010-04-29 Metabolex, Inc. Aryl gpr120 receptor agonists and uses thereof
WO2010060854A1 (en) * 2008-11-25 2010-06-03 Nerviano Medical Sciences S.R.L. Bicyclic pyrazole and isoxazole derivatives as antitumor and antineurodegenerative agents
CN102421827B (zh) 2009-05-15 2014-07-30 日本化药株式会社 具有羟基的生理活性物质的高分子结合体
AR077405A1 (es) 2009-07-10 2011-08-24 Sanofi Aventis Derivados del indol inhibidores de hsp90, composiciones que los contienen y utilizacion de los mismos para el tratamiento del cancer
FR2949467B1 (fr) 2009-09-03 2011-11-25 Sanofi Aventis Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation
US20120283120A1 (en) 2009-09-29 2012-11-08 Takeda Pharmaceutical Company Limited Screening method
WO2011133520A1 (en) 2010-04-19 2011-10-27 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor
KR20140024833A (ko) 2010-11-17 2014-03-03 니폰 가야꾸 가부시끼가이샤 신규한 시티딘계 대사길항제의 고분자 유도체
WO2012103071A2 (en) * 2011-01-25 2012-08-02 Eisai R&D Management Co., Ltd. Compounds and compositions
KR101317656B1 (ko) 2011-06-30 2013-10-15 연세대학교 산학협력단 복제효소 인산화를 조절하는 신규 c형 간염 예방 또는 치료용 조성물
RU2623426C2 (ru) 2011-09-11 2017-06-26 Ниппон Каяку Кабусики Кайся Способ получения блок-сополимера
AU2012332421A1 (en) 2011-11-02 2014-06-05 Synta Pharmaceuticals Corp. Cancer therapy using a combination of Hsp90 inhibitors with topoisomerase I inhibitors
AU2012332424A1 (en) 2011-11-02 2014-06-05 Synta Pharmaceuticals Corp. Combination therapy of Hsp90 inhibitors with platinum-containing agents
US9402831B2 (en) 2011-11-14 2016-08-02 Synta Pharmaceutical Corp. Combination therapy of HSP90 inhibitors with BRAF inhibitors
CN103724269B (zh) * 2012-10-11 2016-12-21 中国科学院上海药物研究所 苯基1,2-异噁唑或苯基1,2-吡唑类化合物及其用途
CN110891941A (zh) 2017-07-18 2020-03-17 拜耳作物科学股份公司 取代的5-(杂)芳基吡唑酰胺及其盐及其作为除草活性物质的用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2713225B1 (fr) * 1993-12-02 1996-03-01 Sanofi Sa N-pipéridino-3-pyrazolecarboxamide substitué.
ATE355279T1 (de) * 1998-08-07 2006-03-15 Novartis Vaccines & Diagnostic Pyrazole als modulatoren des östrogenrezeptors
CN1501928A (zh) 2000-11-02 2004-06-02 斯隆-凯特林癌症研究所 结合hsp90的小分子组合物
AU2002366440A1 (en) * 2001-09-27 2003-09-09 Smithkline Beecham Corporation Chemical compounds
DE60222804T2 (de) 2001-12-21 2008-07-03 Vernalis (Cambridge) Ltd., Abington 3-(2,4)dihydroxyphenyl-4-phenylpyrazole und deren medizinische verwendung

Also Published As

Publication number Publication date
CA2508574A1 (en) 2004-06-17
EP1567151A1 (de) 2005-08-31
JP2006510627A (ja) 2006-03-30
ATE320252T1 (de) 2006-04-15
AU2003285584A1 (en) 2004-06-23
CN1744894A (zh) 2006-03-08
US20070112192A1 (en) 2007-05-17
JP4575779B2 (ja) 2010-11-04
US7803831B2 (en) 2010-09-28
GB0228417D0 (en) 2003-01-08
WO2004050087A1 (en) 2004-06-17
DE60304059T2 (de) 2006-11-16
AU2003285584A8 (en) 2004-06-23
EP1567151B1 (de) 2006-03-15
BR0316146A (pt) 2005-10-25

Similar Documents

Publication Publication Date Title
DE60304059D1 (de) 3-(2-hydroxy-phenyl)-1h-pyrazol-4-carbonsäureamid derivate als hsp90 inhibitoren zur behandlung von krebs
NO20061416L (no) Pyrimidotiofenforbindelser
NO20054195L (no) Isoksazolforbindelser som inhibitorer for varmesjokkproteiner
DE69912581D1 (de) Biarylessigsäure-derivate und ihre verwendung als cox-2 inhibitoren
ATE523492T1 (de) Chinolin- und chinoxalinderivate als inhibitoren der enzymatischen kinaseaktivität
NO20053614L (no) Nye pyridazin-3(2H)-on-derivater
ATE540021T1 (de) Hydroxansäurederivate als inhibitoren der enzymatischen hdac-aktivität
HUP0402376A2 (hu) Imidazol-4-karboxamid-származékok, előállításuk és az ezeket tartalmazó, elhízás kezelésére alkalmas gyógyszerkészítmények
TNSN07348A1 (en) Thiadiazole substituted coumarin derivatives and their use as leukotriene biosynthesis inhibitor
TW200510381A (en) Novel 2-pyridinecarboxamide derivatives
TW200611907A (en) Fused heterocyclic compound
BRPI0509588A (pt) derivados e tetraidronaftiridina e um processo para preparação dos mesmos
MX2011008305A (es) Compuestos de piridazinona.
TW200633991A (en) Chemical compounds
WO2006123165A3 (en) Pyrimidine derivatives as hsp90 inhibitors
WO2009109991A3 (en) Novel hydrazide containing tyrosine kinase inhibitors
DE69332792T2 (de) 4,1-Benzoxazepinderivate als Squalen-Synthetase Inhibitoren und ihre Verwendung zur Behandlung von Hypercholesterämie und als Fungizide
HRP20060124A2 (en) Process for the preparation of n-amino substituted heterocyclic compounds
MX2010000658A (es) Derivados de pirimidina 934.
HUP9903836A2 (hu) Új eljárás Cox-2 inhibítor hatású fenil-szubsztituált 2(5H)-furanonok előállítására
DK1601653T3 (da) Fremgangsmåde til fremstilling af substituerede nikotinsyreestre
MX2010010471A (es) Derivado de tetrahidroisoquinolina novedoso.
UA91033C2 (en) Oxadiazole derivatives as dgat inhibitors
EA200400828A1 (ru) Гетероциклические замещённые фенилсодержащие сульфонамиды широкого спектра действия в качестве ингибиторов протеазы вич
DE60325984D1 (de) 4-aminobenzofuranverbindungen als phosphodiesterase-4-inhibitoren

Legal Events

Date Code Title Description
8364 No opposition during term of opposition